IN188849B - - Google Patents

Info

Publication number
IN188849B
IN188849B IN466MU2000A IN188849B IN 188849 B IN188849 B IN 188849B IN 466MU2000 A IN466MU2000 A IN 466MU2000A IN 188849 B IN188849 B IN 188849B
Authority
IN
India
Application number
Other languages
English (en)
Inventor
Charles Kwok-Fung Chiu
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of IN188849B publication Critical patent/IN188849B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00Ethers; Compounds having groups, groups or groups
    • C07C43/02Ethers
    • C07C43/20Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/215Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring having unsaturation outside the six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/45Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by condensation
    • C07C45/48Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by condensation involving decarboxylation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/56Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds from heterocyclic compounds
    • C07C45/57Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds from heterocyclic compounds with oxygen as the only heteroatom
    • C07C45/59Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds from heterocyclic compounds with oxygen as the only heteroatom in five-membered rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/84Ketones containing a keto group bound to a six-membered aromatic ring containing ether groups, groups, groups, or groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D317/00Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/18Radicals substituted by singly bound oxygen or sulfur atoms
    • C07D317/22Radicals substituted by singly bound oxygen or sulfur atoms etherified
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D317/00Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/26Radicals substituted by doubly bound oxygen or sulfur atoms or by two such atoms singly bound to the same carbon atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00Systems containing two condensed rings
    • C07C2602/02Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IN466MU2000 1999-05-24 2000-05-22 IN188849B (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13557899P 1999-05-24 1999-05-24

Publications (1)

Publication Number Publication Date
IN188849B true IN188849B (hu) 2002-11-09

Family

ID=22468706

Family Applications (1)

Application Number Title Priority Date Filing Date
IN466MU2000 IN188849B (hu) 1999-05-24 2000-05-22

Country Status (25)

Country Link
US (3) US6232476B1 (hu)
EP (1) EP1055658B1 (hu)
JP (2) JP3296809B2 (hu)
KR (1) KR100388176B1 (hu)
CN (3) CN1226265C (hu)
AR (1) AR035990A1 (hu)
AT (1) ATE234269T1 (hu)
AU (1) AU769690B2 (hu)
BR (1) BR0001813B1 (hu)
CA (1) CA2308922C (hu)
DE (1) DE60001599T2 (hu)
DK (1) DK1055658T3 (hu)
ES (1) ES2191597T3 (hu)
HK (1) HK1061843A1 (hu)
HU (1) HUP0001988A3 (hu)
ID (1) ID26146A (hu)
IL (1) IL136231A (hu)
IN (1) IN188849B (hu)
PL (1) PL340237A1 (hu)
PT (1) PT1055658E (hu)
RU (1) RU2195445C2 (hu)
TR (1) TR200001476A2 (hu)
TW (1) TWI231295B (hu)
YU (1) YU26700A (hu)
ZA (1) ZA200002514B (hu)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU26700A (sh) * 1999-05-24 2002-06-19 Pfizer Products Inc. Postupak za cis-1-(2-(4-(6-metoksi-2-fenil-1,2,3,4- tetrahidronaftalen-1-il)fenoksi)etil)pirolidin
PL372727A1 (en) * 2002-03-28 2005-07-25 Pfizer Products Inc. Purified lasofoxifene and a method for purification of racemic lasofoxifene by recrystallization
PA8576201A1 (es) * 2002-07-10 2004-05-26 Pfizer Prod Inc Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco
JP5212931B2 (ja) * 2006-01-26 2013-06-19 学校法人東京理科大学 ラソフォキシフェン及びその類縁体の製造方法
CZ2007373A3 (cs) * 2007-05-29 2008-12-10 Zentiva, A. S Zpusob prípravy lasofoxifenu
CN102424661A (zh) * 2011-10-21 2012-04-25 南开大学 一种偶氮类色素半抗原与人工抗原的合成方法
CN103113323B (zh) * 2013-02-05 2015-11-11 南京华威医药科技开发有限公司 酒石酸拉索昔芬中间体的制备方法
US20180098963A1 (en) 2016-10-11 2018-04-12 Duke University Lasofoxifene treatment of breast cancer
EP3773524A4 (en) 2018-04-10 2021-12-22 Duke University TREATMENT OF BREAST CANCER WITH LASOFOXIFEN
GB202116903D0 (en) 2021-11-18 2022-01-05 Sermonix Pharmaceuticals Inc Lasofoxifene treatment of aromatase-resistant er+ cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3274213A (en) * 1961-09-05 1966-09-20 Upjohn Co Alkoxy-substituted 2-phenyl-1-(tertiary-aminoalkoxy)phenyl-3, 4-dihydronaphthalenes
US3234090A (en) 1962-09-10 1966-02-08 Ciba Geigy Corp Pharmaceutical compositions comprising saturated basic ethers
US3522319A (en) 1964-01-23 1970-07-28 Ciba Geigy Corp Phenol substituted tetrahydronaphthalenes useful as estrogenics
US5552412A (en) * 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
US5552241A (en) * 1995-05-10 1996-09-03 Electrochemical Systems, Inc. Low temperature molten salt compositions containing fluoropyrazolium salts
UA51676C2 (uk) * 1995-11-02 2002-12-16 Пфайзер Інк. (-)цис-6(s)-феніл-5(r)[4-(2-піролідин-1-ілетокси)феніл]-5,6,7,8-тетрагідронафталін-2-ол d-тартрат, спосіб його одержання, спосіб лікування захворювань, що піддаються лікуванню агоністами естрогену, та фармацевтична композиція
YU26700A (sh) * 1999-05-24 2002-06-19 Pfizer Products Inc. Postupak za cis-1-(2-(4-(6-metoksi-2-fenil-1,2,3,4- tetrahidronaftalen-1-il)fenoksi)etil)pirolidin

Also Published As

Publication number Publication date
ZA200002514B (en) 2002-02-22
HUP0001988A3 (en) 2002-04-29
US6232476B1 (en) 2001-05-15
DE60001599D1 (de) 2003-04-17
ID26146A (id) 2000-11-30
AU3636200A (en) 2000-11-30
RU2195445C2 (ru) 2002-12-27
KR20010029733A (ko) 2001-04-16
TWI231295B (en) 2005-04-21
US20020042524A1 (en) 2002-04-11
IL136231A0 (en) 2001-05-20
HK1061843A1 (en) 2004-10-08
BR0001813A (pt) 2001-01-02
JP3296809B2 (ja) 2002-07-02
PT1055658E (pt) 2003-07-31
PL340237A1 (en) 2000-12-04
CA2308922C (en) 2007-05-01
KR100388176B1 (ko) 2003-06-19
JP3600206B2 (ja) 2004-12-15
JP2002205990A (ja) 2002-07-23
YU26700A (sh) 2002-06-19
BR0001813B1 (pt) 2011-03-22
HUP0001988A2 (en) 2001-03-28
EP1055658A2 (en) 2000-11-29
HU0001988D0 (en) 2000-08-28
CN1226265C (zh) 2005-11-09
DK1055658T3 (da) 2003-04-22
DE60001599T2 (de) 2003-11-13
US6395911B1 (en) 2002-05-28
TR200001476A2 (tr) 2001-02-21
CN1280128A (zh) 2001-01-17
CN1271030C (zh) 2006-08-23
EP1055658A3 (en) 2000-12-13
ES2191597T3 (es) 2003-09-16
CN1502598A (zh) 2004-06-09
AR035990A1 (es) 2004-08-04
CA2308922A1 (en) 2000-11-24
JP2000327670A (ja) 2000-11-28
IL136231A (en) 2005-06-19
AU769690B2 (en) 2004-01-29
ATE234269T1 (de) 2003-03-15
US6323345B1 (en) 2001-11-27
CN1502597A (zh) 2004-06-09
EP1055658B1 (en) 2003-03-12

Similar Documents

Publication Publication Date Title
BE2018C020I2 (hu)
BE2016C007I2 (hu)
BE2015C057I2 (hu)
BE2013C051I2 (hu)
BE2012C036I2 (hu)
BE2011C004I2 (hu)
BE2010C011I2 (hu)
JP2002526908A5 (hu)
BE2008C046I2 (hu)
BE1025464I2 (hu)
BRPI0017527B8 (hu)
JP2002514532A5 (hu)
BE2008C047I2 (hu)
BRPI0001672A2 (hu)
JP2002510085A5 (hu)
JP2002530205A5 (hu)
JP2002514001A5 (hu)
BRPI0001542A2 (hu)
JP2002505864A5 (hu)
JP2002520191A5 (hu)
JP2002503593A5 (hu)
JP2002525804A5 (hu)
IN191496B (hu)
JP2002524008A5 (hu)
IN2001MU01108A (hu)